Data from the POWER clinical trials demonstrate a consistent FUZEON effect in treatment-experienced patients when FUZEON was added to a boosted PI regimen, with more patients achieving undetectable viral load (<50 copies/mL) than those who did not receive FUZEON as part of their antiretroviral regimen.^1-4



Click here to read the full Prescribing Information for FUZEON.

Click here to read the Important Safety Information.

1. Lazzarin A, Queiroz-Telles F, Frank I, et al. TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis. 16th International AIDS Conference. August 13-18, 2006. Toronto, Canada. Abstract TUAB0104.
2. Katlama. TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: Week 24 primary efficacy analysis of POWER 1 (TMC114-C213). 3rd IAS Conference on HIV Pathogenesis and Treatment. July 24-27, 2005; Rio de Janeiro, Brazil. Abstract WeOaLB0102.
3. Wilkin T, Haubrich R, Steinhart CR, et al. TMC114/r superior to standard of care in 3-class experienced patients: 24-wks primary analysis of the POWER 2 study (C202). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). December 16-19, 2005; Washington, DC. Abstract 2860.
4. Prezista (darunavir) Tablets application no. 021976. Available at: http://www.fda.gov/cder/foi/nda/2006/021976s000_ SprycelTOC.htm. Accessed September 26, 2006.